| Literature DB >> 27785042 |
Jia-Jun Li1, Wen-Xiang Huang1, Zheng-Yu Shi1, Qiu Sun1, Xiao-Juan Xin1, Jin-Qiu Zhao1, Zhen Yin1.
Abstract
BACKGROUND: Fever of unknown origin (FUO) has always been a challenging problem for physicians since it was first reported half a century ago. This study aimed to investigate the clinical features of FUO and to compare the clinical significance of the classical diagnostic criteria and the Chinese revised diagnostic criteria of FUO.Entities:
Keywords: comparison; diagnostic criteria; drug design; fever of unknown origin
Year: 2016 PMID: 27785042 PMCID: PMC5067017 DOI: 10.2147/TCRM.S97863
Source DB: PubMed Journal: Ther Clin Risk Manag ISSN: 1176-6336 Impact factor: 2.423
Comparison of the general conditions between the two groups
| Group | Group A (n=50) | Group B (n=90) | Total (n=140) | |
|---|---|---|---|---|
| Male/female, n | 27/23 | 56/34 | 83/57 | 0.343 |
| Age, years | 42±18 | 46±18 | 44±18 | 0.159 |
| Duration of hospitalization, days | 23±17 | 19±19 | 20±18 | 0.303 |
| Duration of fever in hospital, days | 12±18 | 11±12 | 12±11 | 0.654 |
Notes: Data presented as mean ± standard deviation unless otherwise noted. Results are in response to an independent samples t-test.
Comparison of the final diagnoses between the two groups
| Etiology | Group A | Group B | Total | |
|---|---|---|---|---|
| Infections | 17 cases (34%) | 28 (31%) | 45 (32%) | 0.726 |
| General bacterial infections | 7 | 18 | 25 | |
| Respiratory tract infections | 1 | 8 | 9 | |
| Biliary tract infections | 1 | 2 | 3 | |
| Urinary tract infections | 0 | 2 | 2 | |
| Septicemia | 1 | 4 | 5 | |
| Hepatapostema | 2 | 0 | 2 | |
| Intra-abdominal abscess | 1 | 1 | 2 | |
| Infectious endocarditis | 1 | 0 | 1 | |
| Typhoid fever | 0 | 1 | 1 | |
| Tuberculosis | 6 | 7 | 13 | |
| Pulmonary tuberculosis | 2 | 1 | 3 | |
| Miliary tuberculosis | 3 | 2 | 5 | |
| Tuberculous pleurisy | 1 | 0 | 1 | |
| Spinal tuberculosis | 0 | 3 | 3 | |
| Pelvic tuberculosis | 0 | 1 | 1 | |
| Viral infections | 3 | 0 | 3 | |
| Infectious mononucleosis | 2 | 0 | 2 | |
| Parvovirus infection | 1 | 0 | 1 | |
| Fungal infections | 0 | 1 | 1 | |
| Parasitic infections | 1 | 2 | 3 | |
| Kala-azar | 1 | 1 | 2 | |
| Malaria | 0 | 1 | 1 | |
| Neoplasms | 4 (8%) | 8 (9%) | 12 (9%) | 0.857 |
| Hematological malignancy | 2 | 6 | 8 | |
| Non-Hodgkin’s lymphoma | 2 | 3 | 5 | |
| Leukemia | 0 | 3 | 3 | |
| Malignant solid tumor | 2 | 2 | 4 | |
| Hepatoma | 0 | 1 | 1 | |
| Malignant peritoneal mesothelioma | 1 | 0 | 1 | |
| Malignancy of undefined primary origin | 1 | 1 | 2 | |
| Connective tissue diseases | 7 (14%) | 11 (12%) | 18 (13%) | 0.763 |
| Adult-onset Still’s disease | 7 | 4 | 11 | |
| Systemic lupus erythematosus | 0 | 2 | 2 | |
| Mixed connective tissue disease | 0 | 1 | 1 | |
| Ankylosing spondylitis | 0 | 1 | 1 | |
| Microscopic polyangiitis | 0 | 1 | 1 | |
| Still’s disease | 0 | 1 | 1 | |
| Erythema nodosum | 0 | 1 | 1 | |
| Miscellaneous – other disorders | 6 (12%) | 8 (9%) | 14 (10%) | 0.557 |
| Drug fever | 0 | 1 | 1 | |
| Necrotizing lymphadenitis | 1 | 1 | 2 | |
| Subacute thyroiditis | 4 | 4 | 8 | |
| Hashimoto’s thyroiditis | 0 | 1 | 1 | |
| Autoimmune liver diseases | 0 | 1 | 1 | |
| Myocarditis | 1 | 0 | 1 | |
| Undiagnosed | 16 (32%) | 35 (39%) | 51 (36%) | 0.417 |
| Total | 50 (100%) | 90 (100%) | 140 (100%) |
Comparison of the definite diagnosis times between the two groups
| Group | Group A (n=34) | Group B (n=55) | Total (n=89) | |
|---|---|---|---|---|
| Definite diagnosis time, days | 10.77±10.75 | 11.82±16.46 | 11.42±14.48 | 0.433 |
| Distribution of diagnosis data | ||||
| ≤3 days | 8 (24%) | 20 (36%) | 28 (31%) | 0.205 |
| 4–7 days | 10 (29%) | 13 (24%) | 23 (26%) | 0.545 |
| ≥8 days | 16 (47%) | 22 (40%) | 38 (43%) | 0.513 |
Notes:
Data presented as mean ± standard deviation. Results are in response to an independent samples t-test.
Comparison of the conclusive diagnostic methods between the two groups
| Group | Conclusive diagnostic method
| |||||
|---|---|---|---|---|---|---|
| Clinical | Laboratory | Imaging | Bacteriological | Pathological | Therapeutical | |
| Group A (n=34) | 10 (31%) | 6 (18%) | 10 (30%) | 1 (3%) | 6 (15%) | 1 (3%) |
| Group B (n=55) | 17 (31%) | 5 (9%) | 16 (29%) | 4 (7%) | 13 (24%) | 0 (0%) |
| Total (n=89) | 27 (31%) | 11 (12%) | 26 (29%) | 5 (6%) | 19 (21%) | 1 (1%) |
| 0.881 | 0.233 | 0.947 | 0.389 | 0.503 | 0.201 | |
Common symptoms found in the diagnostic categories
| Symptom | Infections
| Neoplasms
| CTDs
| Others
| Total
|
|---|---|---|---|---|---|
| n=45 | n=12 | n=18 | n=14 | n=89 | |
| Cough | 18 | 4 | 7 | 2 | 31 |
| Sore throats | 9 | 0 | 12 | 8 | 29 |
| Hepatosplenomegaly | 18 | 6 | 10 | 2 | 36 |
| Weight loss (>5 kg) | 15 | 4 | 7 | 3 | 29 |
| Skin rash | 5 | 0 | 10 | 4 | 19 |
| Myalgia | 7 | 1 | 5 | 3 | 16 |
| Night sweats | 12 | 0 | 0 | 1 | 13 |
| Arthralgia | 6 | 2 | 5 | 0 | 13 |
| Lymphadenectasis | 8 | 1 | 3 | 2 | 14 |
| Abdominal tenderness | 9 | 2 | 1 | 2 | 14 |
| Lung rales | 4 | 0 | 3 | 1 | 8 |
| Abdominal discomfort | 3 | 3 | 1 | 2 | 9 |
Abbreviation: CTD, connective tissue disease.
Inflammatory markers among the diagnostic categories
| Diagnostic categories | WBC (×109/L) | ESR (mm/h) | CRP (mg/L) | PCT (ng/mL) |
|---|---|---|---|---|
| Infections (n=45) | 9.11±5.76 | 53.77±43.23 | 95.76±76.45 | 1.72±2.96 |
| Neoplasms (n=12) | 13.56±12.53 | 111.9±47.91 | 160.94±101.64 | 0.95±1.57 |
| CTDs (n=18) | 13.55±6.95 | 87.77±30.42 | 110.97±60.92 | 0.69±1.05 |
| Miscellaneous disorders (n=15) | 8.31±4.08 | 75.5±37.4 | 70.11±61.32 | 0.23±0.39 |
| Total (n=89) | 10.51±7.46 | 71.77±46.11 | 102.12±78.7 | 1.15±2.29 |
Notes:
P-value represents the index in the groups compared to “infections” group.
P-value represents the index in the groups compared to miscellaneous disorders group.
Abbreviations: CTD, connective tissue disease; WBC, white blood cell count; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; PCT, procalcitonin.
Comparison of the discharge conditions of undiagnosed cases between two groups
| Groups | Temperature recovery | Still febrile | Dead |
|---|---|---|---|
| Groups A (n=16) | 6 (38%) | 9 (58%) | 1 (6%) |
| Groups B (n=35) | 13 (37%) | 22 (63%) | 0 (0%) |
| Total (n=51) | 19 (37%) | 31 (61%) | 1 (2%) |
| 0.98 | 0.654 | 0.135 |